(Reuters) – Aktis Oncology said on Tuesday it will collaborate with Eli Lilly to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties on sales.
(Reporting by Christy Santhosh; Editing by Krishna Chandra Eluri)
Comments